Clinical Trial

Blood Markers of Early Pancreas Cancer

Study Description

Blood Markers of Early Pancreas Cancer

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Diagnostic Test - Mixed Meal Tolerance Test

The goal of the test is to determine hormone secretion from the pancreas and small intestine in response to the mixed meal.

Diagnostic Test - Hemoglobin A1c

This test provides the average level of blood glucose over the last 3 months.

Diagnostic Test - Other exploratory blood biomarkers

Other exploratory blood biomarkers including cell free DNA and other markers in development

Additional Information

Official Study Title

A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer

Clinical Trial ID

NCT03568630

ParticipAid ID

b8283e